Newron Pharmaceuticals SpA ( (CH:NWRN) ) has issued an announcement.
Newron Pharmaceuticals reported a net profit of EUR 15.8 million for 2024, a significant turnaround from the previous year’s loss, driven by licensing revenues from agreements with EA Pharma/Eisai Group and Myung In Pharm. The company has strengthened its financial position and expanded its market reach through strategic partnerships and capital measures, positioning itself for further growth in 2025 with plans to advance Evenamide’s development and potentially register its shares in the USA.
More about Newron Pharmaceuticals SpA
Newron Pharmaceuticals is a biopharmaceutical company specializing in developing innovative therapies for central and peripheral nervous system disorders. Its lead drug candidate, Evenamide, is a first-in-class glutamate modulator aimed at treating treatment-resistant schizophrenia and patients inadequately responding to current therapies. Newron has established licensing agreements for Evenamide’s development and marketing in Asia and has a successful history with CNS therapies, including its Parkinson’s drug, Xadago.
Technical Sentiment Signal: Sell
Current Market Cap: $181.1M
For a thorough assessment of NWRN stock, go to TipRanks’ Stock Analysis page.